Skip to main content

Sinocelltech Group

Sinocelltech Group Ltd is a Chinese biopharmaceutical company developing recombinant proteins, monoclonal antibodies, and vaccines. The company researches, produces, and commercializes biologic candidates, highlighted by its recombinant human coagulation factor VIII (Anjiavin) for hemophilia A, alongside anti-PD-1 antibodies and COVID-19 vaccine candidates. Main revenue drivers comprise commercial sales of recombinant coagulation factor products, biopharmaceutical milestone payments, and research grants. Sinocelltech Group serves hematologists, hospital networks, prescription pharmacies, and hemophilia patients across China. The company holds an innovative market position in China as a pioneer in domestic recombinant coagulation factor production and biological therapeutic development. Headquartered in Beijing, China, it is listed on the STAR Market of the Shanghai Stock Exchange.

2 of the funds FundTelligence covers report a position in Sinocelltech Group.

Legal name
Sinocelltech Group Ltd
Sector
Health Care
Country
China
Funds holding it
2

Funds holding Sinocelltech Group

Loading...